SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. MYOK, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018.
"MyoKardia continues to make encouraging progress toward our mission of changing the world for patients with serious cardiovascular disease. Within just the past few months, we have initiated the MAVA-LTE clinical study of mavacamten and the Phase 2a portion of our active clinical trial of MYK-491, unveiled three new preclinical programs and through our efforts with the SHaRe registry, our MyoSeeds grant program and newly formed collaboration with 23andMe, demonstrated our commitment to supporting the HCM community and helping to build awareness of this debilitating and progressive disease," said Tassos Gianakakos, Chief Executive Officer. "We'll be sharing additional progress across our programs in the coming weeks, with the presentation of clinical, preclinical and registry data at the upcoming American Heart Association Scientific Sessions and the release of topline data from our Phase 1b clinical trial of MYK-491 in patients with dilated cardiomyopathy before the end of the year."
Recent Clinical Program Highlights
Mavacamten for Hypertrophic Cardiomyopathy (HCM)
- Dosed first patient in MAVA Long-Term Extension (LTE) Study of Mavacamten in HCM: The MAVA-LTE study will assess long-term safety of mavacamten, as well as its effects on hypertrophic cardiomyopathy (HCM) symptoms and cardiac function in patients who successfully complete either MyoKardia's MAVERICK-HCM or EXPLORER-HCM clinical trials of mavacamten. Data from the MAVA-LTE clinical trial, along with results of the pivotal Phase 3 EXPLORER-HCM trial, are intended to support the registration submission for mavacamten for the treatment of obstructive HCM (oHCM).
- Reported encouraging initial data from PIONEER Open-Label Extension (OLE) Study: Twelve of twenty patients with oHCM who previously completed MyoKardia's Phase 2 PIONEER-HCM study of mavacamten for the treatment of symptomatic oHCM have enrolled in the PIONEER-OLE trial. Interim data for seven patients at twelve weeks of treatment with mavacamten demonstrated statistically significant reductions in left ventricular outflow tract (LVOT) obstruction compared to baseline. All patients maintained ejection fraction well in the normal range of greater than 50 percent, and there have been no significant adverse events reported. Individualized dose adjustments in PIONEER-OLE are consistent with the regimen being used in MyoKardia's pivotal Phase 3 EXPLORER-HCM trial of mavacamten for the treatment of oHCM.
- Announced acceptance of twelve abstracts at the 2018 AHA Scientific Sessions: Among the highlights of the data being presented are an analysis of mavacamten's effect on left ventricular relaxation based on an analysis of patient data from the Phase 2 PIONEER-HCM clinical trial, which will be presented in a poster session on Saturday, November 10, and preclinical data examining the in vivo effect of myosin inhibition in a proprietary large-animal model of non-obstructive hypertrophic cardiomyopathy (nHCM), which will be shared in an oral presentation on Sunday, November 11. MyoKardia management will host a call on Monday, November 12 at 8:00 a.m. ET to review the data being presented.
- Published new data from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) in Circulation: Results from a multicenter, international, longitudinal study of data from nearly 4,600 HCM patients were published in the October 2, 2018 issue of Circulation. These data revealed that HCM patients are at substantially elevated risks of long-term complications and comorbidities, as well as increased mortality rates compared to that of the general U.S. population.
- Launched the MyoSeeds™ Grant Program: MyoKardia issued a call for proposals for its MyoSeeds initiative to support original, independent research in the biology and underlying mechanisms of cardiomyopathies and precision treatment for heart disease. Through this program, MyoKardia will fund up to four awards, with a total investment of up to $1 million in funding over 2018-2019. Grants will be awarded by December 31, 2018.
- Established partnership with 23andMe to form the first-of-its-kind HCM patient community: MyoKardia and 23andMe will create a patient community where 23andMe customers can access regularly-updated disease information and HCM research opportunities. De-identified genotypic and phenotypic data will be collected to provide new insights into how HCM manifests across diverse patient groups. This resource is expected to launch in 2019.
MYK-491 for Systolic Dysfunction
- Advanced MYK-491 to Phase 2a Study: Enrollment of patients in the ongoing Phase 1b study of MYK-491 has completed, and MyoKardia plans to report topline data in the fourth quarter of 2018. Additionally, the protocol for this study was recently modified to incorporate a Phase 2a multiple-ascending dose trial in patients with stable heart failure. Enrollment in the Phase 2a clinical trial has begun, with data anticipated in late 2019.
- Reported healthy volunteer data supporting initial proof-of-mechanism: At its recent R&D Day, MyoKardia detailed results of its Phase 1a study in healthy volunteers, showing that MYK-491, the company's lead compound targeting impaired systolic function, increased cardiac contractility by 5-20 percent across multiple echocardiographic parameters at higher drug concentrations, with minimal impact on diastolic function. These data are consistent with preclinical data.
Research Pipeline
- Introduced three new research programs, each with distinct mechanisms targeting diseases of cardiac contractility: At its recent R&D Day on October 30th, 2018, MyoKardia unveiled three new research programs: MYK-224, the company's second candidate addressing HCM, which the company anticipates will enter a Phase 1 clinical study in 2019; ACT-1, a proprietary, wholly-owned cardiac muscle activator which is being developed for the treatment of genetic dilated cardiomyopathy (DCM); and LUS-1, the first known compound to specifically target impaired cardiac relaxation for patients with diseases of diastolic dysfunction, also wholly owned.
Third Quarter 2018 Financial Results
- Cash Position: Cash, cash equivalents and investments (short-term and long-term) as of September 30, 2018 were $411.6 million, compared to $276.4 million as of December 31, 2017. The increase in the company's cash position is primarily attributable to MyoKardia's follow-on financing in the second quarter of 2018, which raised $181.9 million in net proceeds.
- Revenues: Collaboration and license revenue was $9.2 million during the third quarter of 2018, compared with $3.1 million during the third quarter of 2017. For the nine months ended September 30, 2018, collaboration and license revenue was $21.2 compared to $8.5 million for the first nine months of 2017. The increase in collaboration revenue in 2018 is attributable to the adoption of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, the $45 million payment received from Sanofi S.A. (Sanofi) in the first quarter of 2017 is now being recognized based on research and development costs incurred in a particular period relative to the estimated total program costs to be incurred in the two-year period ending December 31, 2018.
- R&D Expenses: Research and development expenses were $15.9 million, net of Sanofi reimbursement credits of $7.7 million, for the third quarter of 2018, up from $14.4 million for the same period in 2017. There were no reimbursement credits in the three months ending September 30, 2017. R&D expenses in the first nine months of 2018 were $49.7 million, net of reimbursement credits of $14.8 million, up from $40.0 million for the same period in 2017. The $14.8 million includes $2.6 million due from Sanofi for the MYK-224 R&D program. Cash received from Sanofi for R&D reimbursements on the mavacamten program totaled $6.9 million and $18.7 million for the three- and nine-month periods, respectively. The increase in R&D expenses was driven by clinical trial activity for mavacamten, MYK-491 and preclinical programs, an increase in headcount, and stock-based compensation expense.
- G&A Expenses: General and administrative expenses were $11.0 million for the three months ended September 30, 2018, compared to $5.9 million for the same period in 2017. For the first nine months of 2018, G&A expenses were $27.2 million compared to $16.4 million in the same period in 2017. The increase in G&A expenses was primarily attributable to an increase in headcount, stock-based compensation expense, facilities-related and other administrative expenses.
- Net Loss: Net loss was $15.8 million ($0.39 per share) for the third quarter of 2018, compared to a net loss of $16.7 million ($0.50 per share) for the third quarter of 2017. For the nine months ended September 30, 2018, net loss was $52.0 million ($1.38 per share) compared to $46.9 million ($1.47 per share) during the same period of 2017.
Based on the company's current balance of cash and investments, plus anticipated payments from Sanofi, MyoKardia estimates having sufficient funds to execute on current operating plans into 2021.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia's initial focus is on the development of small molecule therapeutics aimed at the cardiac muscle proteins that modulate cardiac muscle contraction and underlie diseases of systolic and diastolic dysfunction. Based on an in-depth understanding of disease biology, MyoKardia applies a precision medicine approach to develop its therapeutic candidates for patient populations with shared characteristics, such as causal genetic mutations or disease subtypes. MyoKardia's most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin intended to reduce hypercontractility. Mavacamten has advanced into a pivotal Phase 3 clinical trial, known as EXPLORER-HCM in patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM). MyoKardia is also developing mavacamten in a second indication, non-obstructive HCM, in the Phase 2 MAVERICK-HCM clinical trial. MYK-491, MyoKardia's second product candidate, is designed to increase cardiac output among patients with systolic heart dysfunction by increasing the overall extent of the heart's cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1b/2a study in stable heart failure patients. MyoKardia has formed a collaboration with Sanofi to support the commercialization of mavacamten outside the U.S. and for MYK-491's worldwide late-stage development and commercialization. MyoKardia's mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten and MYK-491, the progress of and availability of data from the Company's ongoing Phase 3 EXPLORER-HCM trial of mavacamten in oHCM patients, Phase 2 MAVERICK-HCM trial of mavacamten in nHCM patients and PIONEER-OLE study of mavacamten, the commencement of the Company's planned LTE study of mavacamten, the progress of and availability of data from the Company's ongoing Phase 1 study of MYK-491 in DCM patients, the commencement of the Company's planned Phase 2 study of MYK-491, the advancement of the Company's research programs, as well as the timing of these events, and the Company's expected cash runway and ability to receive additional payments from its collaboration agreement with Sanofi, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in our Annual Report on Form 10-K for the year ended December 31, 2017, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Michelle Corral
Corporate Communications & Investor Relations
MyoKardia, Inc.
650-351-4690
mcorral@myokardia.com
Hannah Deresiewicz (Investors)
Stern Investor Relations, Inc.
212-362-1200
hannahd@sternir.com
Steven Cooper (Media)
Edelman
415-486-3264
steven.cooper@edelman.com
| MYOKARDIA, INC. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| September 30, | December 31, | |||||||
| 2018 | 2017 | |||||||
| (As Revised) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 335,279 | $ | 224,571 | ||||
| Short-term investments | 43,845 | 31,933 | ||||||
| Receivable from collaboration partner | 2,565 | 1,013 | ||||||
| Prepaid expenses and other current assets | 2,566 | 1,876 | ||||||
| Total current assets | 384,255 | 259,393 | ||||||
| Property and equipment, net | 4,905 | 3,147 | ||||||
| Long-term investments | 32,506 | 19,900 | ||||||
| Restricted cash and other | 2,312 | 368 | ||||||
| Total assets | $ | 423,978 | $ | 282,808 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 2,454 | $ | 2,301 | ||||
| Accrued liabilities | 18,790 | 11,639 | ||||||
| Prepayment from collaboration partner | 10,943 | 4,432 | ||||||
| Deferred revenue | 12,400 | 33,558 | ||||||
| Total current liabilities | 44,587 | 51,930 | ||||||
| Other long-term liabilities | 54 | 202 | ||||||
| Total liabilities | 44,641 | 52,132 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding | — | — | ||||||
| Common stock, $0.0001 par value, 150,000,000 and 150,000,000 shares authorized at September 30, 2018 and December 31, 2017, respectively; 40,240,530 and 35,812,791 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively | 4 | 4 | ||||||
| Additional paid-in capital | 566,432 | 365,719 | ||||||
| Accumulated other comprehensive loss | (222 | ) | (192 | ) | ||||
| Accumulated deficit | (186,877 | ) | (134,855 | ) | ||||
| Total stockholders' equity | 379,337 | 230,676 | ||||||
| Total liabilities and stockholders' equity | $ | 423,978 | $ | 282,808 | ||||
| MYOKARDIA, INC. | ||||||||||||||||
| Condensed Consolidated Statement of Operations and Comprehensive Loss | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| (As Revised) | (As Revised) | |||||||||||||||
| Collaboration and license revenue | $ | 9,188 | $ | 3,077 | $ | 21,158 | $ | 8,488 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 15,910 | 14,361 | 49,746 | 39,967 | ||||||||||||
| General and administrative | 10,957 | 5,884 | 27,182 | 16,442 | ||||||||||||
| Total operating expenses | 26,867 | 20,245 | 76,928 | 56,409 | ||||||||||||
| Loss from operations | (17,679 | ) | (17,168 | ) | (55,770 | ) | (47,921 | ) | ||||||||
| Interest and other income, net | 1,890 | 447 | 3,748 | 977 | ||||||||||||
| Net loss | (15,789 | ) | (16,721 | ) | (52,022 | ) | (46,944 | ) | ||||||||
| Other comprehensive gain (loss) | 37 | 2 | (30 | ) | 60 | |||||||||||
| Comprehensive loss | (15,752 | ) | (16,719 | ) | (52,052 | ) | (46,884 | ) | ||||||||
| Net loss attributable to common stockholders | $ | (15,789 | ) | $ | (16,721 | ) | $ | (52,022 | ) | $ | (46,944 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.39 | ) | $ | (0.50 | ) | $ | (1.38 | ) | $ | (1.47 | ) | ||||
| Weighted average number of shares used to compute net loss per share attributable to common stockholders, basic and diluted | 40,116,644 | 33,525,567 | 37,765,631 | 31,951,631 | ||||||||||||
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
